Navigation Links
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
Date:6/13/2010

g pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.  Only the FDA c
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
3. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
4. Vivakor Confirms Record Date of Stock Dividend
5. New study confirms exotic electric properties of graphene
6. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
7. Analysis confirms that nano-related research has strong multidisciplinary roots
8. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
11. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 The global ... 8,020.1 million by 2020, according to a new study ... medicine and theranostics, and the subsequent introduction of advanced ... driving market growth over the next six years. Moreover, ... diseases such as cancer, coupled with disease triggering lifestyle ...
(Date:7/31/2014)... Wash. , July 31, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... second quarter 2014 financial results will be released on ... host a conference call and live webcast at 4:30 ...
(Date:7/31/2014)... MA (PRWEB) July 31, 2014 Boston’s ... finds itself flush with innovative adult stem cell biotechnologies. ... patents and has three additional patent applications currently ... , The patented inventions address two of the most ... regenerative medicine. Adult stem cells are difficult to ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... of Iowa and the University of Missouri (MU) have developed ... closely mimic the disease in human infants. The striking similarities ... with CF suggest that this new model will help improve ... new treatments. The study is published in the Sept. 26 ...
... Complement Inhibition and,Impact of Soliris on Patients Living ... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) has received ... Product for Soliris(R) (eculizumab). The Award,recognizes the scientific ... the impact the drug is,having on the lives ...
... Industry Leaders to Spearhead and Expand Home ... Health Care Services Business, CHICAGO, ... focused exclusively on the health care,industry, announced today that it has ... to acquire a controlling interest in,CareCentrix. The firm also announced that ...
Cached Biology Technology:Researchers develop new model for cystic fibrosis 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix 2Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix 3Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix 4
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
(Date:7/31/2014)... German . ... to a sponge that soaks up liquids. Hence, these ... greenhouse gases. However, loading of many MOFs is inhibited ... now report in Nature Communications that the ... This can be prevented by water-free synthesis and storing ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2
... its fluid membranes to carry out critical ... or sorting proteins.,Because membranes are fluid and ... in detail has always been,difficult. But a ... of physics at Carnegie Mellon University, provides ...
... Carbon nanotubes are 10,000 times thinner than a human ... diamonds. They conduct heat and electricity with efficiency that ... in everything from concrete and clothes to bicycle parts ... wonder material for what could become a multi-billion dollar ...
... crops have been widely adopted by American farmers. In ... European Union (EU) imposed a 6-year freeze (19982004) on ... aid to African nations was rejected by the recipient ... contributed to this decision. , Lori Unruh Snyder, Department ...
Cached Biology News:Carnegie Mellon develops computer model to study cell membrane dynamics 2Carnegie Mellon develops computer model to study cell membrane dynamics 3Making sure the wonder materials don't become the wonder pollutant 2
... Microarrays designed for pathway studies, ... protein (PTB) Studies built on the ... synthesis platform. These microarrays are available ... Peptide Microarray Service. Custom ...
... normal Mega Western Protein Array was developed ... Western Protein Arrays are manufactured using high ... sources. A protein sample from each of ... a Protein molecular weight marker on a ...
... Superior Protein Detection and Quantitation Over ... Proteomic Imaging System is a highly sensitive ... life science research applications. ProXPRESS 2D provides ... dyes in the UV and VIS spectrum ...
... 7 lanes of total ... brain tissue including: precentral ... lobe, temporal lobe, parietal ... cerebellum. Patent/trademark/license (electronic): Manufactured ...
Biology Products: